Company Profile
Sigilon Therapeutics, Inc
Company Overview
Sigilon is developing curative treatments for chronic diseases using new biomaterials that can shield implanted cells from immune attack. Treatments based on the Sigilon technology platform include cell implants that act as responsive “living pills,” providing more natural control for diseases currently treated with intermittent injection or infusion. These diseases include genetic disorders that require protein replacement as well as disorders that require dynamic protein delivery such as type 1 diabetes. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life. Sigilon technology originated from research conducted at the Massachusetts Institute of Technology and Harvard Medical School. Based in Cambridge, Massachusetts, Sigilon was founded with major support from Flagship Pioneering. Sigilon is also exploring partnering opportunities in order to maximize the impact of its groundbreaking technology.
Company History
Sigilon was founded by Flagship Pioneering in 2016, Sigilon has grown rapidly and marked promising milestones in the development of its Living Therapeutics product platform with Afibromer™ . In April of 2018 Sigilon formed it's first partnership with Eli Lilly in diabetes.